Perrigo's Next Private Label First Lands With Second Thoughts On Outlook

Oct 03 2017

• By Malcolm Spicer

Listen to this article

The launch of a private label version 24HR OTC heartburn treatment comes with Perrigo in need of another high-selling product to boost revenues in its core business, OTC private label. But analysts call for Perrigo to do more to grow in new markets.

Perrigo Co. PLC is optimistic that its newly launched private label version of Nexium 24HR OTC heartburn treatment will provide a needed boost to its core business of OTC private label products. It's both the first-to-market OTC generic version of the product and builds on much higher brand sales than other previous private label launches of proton pump inhibitors.

Esomeprazole magnesium 20 mg delayed-release capsules, indicated to treat frequent heartburn, is now available to US retailers, Perrigo said on...

More from Marketing & Advertising

India And Pakistan Boost Transparency In Industry-Doctor Interactions
Sep 12 2024
• By Vibha Sharma
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
Celebs Bring Extra Scrutiny To Advertisements, US FDA Tells AbbVie
Sep 11 2024
• By Sarah Karlin-Smith
AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.
Misconstruing Single-Arm Study Data Lands BMS In Trouble With US FDA
Aug 08 2024
• By Sarah Karlin-Smith
The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.
Severe Misconduct, Repeat Offending And Underreporting: UK/EU Codes Come Under Fire
Aug 05 2024
• By Neena Brizmohun
The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.

More from Compliance

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments
Sep 25 2024
• By Francesca Bruce
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
India And Pakistan Boost Transparency In Industry-Doctor Interactions
Sep 12 2024
• By Vibha Sharma
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency
Sep 12 2024
• By Bridget Silverman
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.